<DOC>
	<DOCNO>NCT01818245</DOCNO>
	<brief_summary>This study include two group ( cohort ) participant : In Group A , study look amount LY2605541 present body inject 3 different location body participant . At least 16 day pas injection . In Group B , study look body absorbs , distributes , get rid LY2605541 participant age 65 . Participants may enroll one group .</brief_summary>
	<brief_title>A Study LY2605541 Healthy Participants Elderly</brief_title>
	<detailed_description />
	<criteria>Cohort A : overtly healthy male female participant , determine medical history physical examination , age ≥18 ≤55 year age Cohort B : male female elderly ( ≥65 year age ) participant overtly healthy , stable , chronic medical condition [ include Type 2 Diabetes Mellitus ( T2DM ) ] , investigator 's opinion , significantly alter disposition drug , place participant increase risk participate study , interfere interpretation data Male participant agree use reliable method birth control study 3 month follow last dose investigational product Female participant woman childbearing potential test negative pregnancy time screen base urine pregnancy test agree use reliable method birth control study 1 month follow last dose investigational product Female participant postmenopausal woman , woman childbearing potential due surgical sterilization ( least 3 month surgical hysterectomy , least 3 month bilateral oophorectomy bilateral tubal ligation/occlusion without hysterectomy ) confirm medical history , menopause Have body mass index ( BMI ) 18.5 40 kilogram per meter square ( kg/m^2 ) , inclusive time admission Period 1 Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Are participant intend start change diet lose weight study ; participant expect maintain approximate current weight throughout study Are excessive smoker ( &gt; 10 cigarette per day ) ; participant smoke less equal ( ≤ ) 10 cigarette per day must able stop smoking whilst resident clinical research unit ( CRU ) Healthy Participants Cohort A Have Type 1 Diabetes Mellitus ( T1DM ) , Type 2 Diabetes Mellitus ( T2DM ) , fast blood glucose ( BG ) great ( &gt; ) 110 milligram per deciliter ( mg/dL ) [ 6.1 millimoles per liter ( mmol/L ) ] glycated hemoglobin ( HbA1c ) &gt; 6.2 % Intend use overthecounter medication within 7 day prescription medication within 14 day prior dose ( apart contraceptive medication , vitamin/mineral supplement , occasional paracetamol , thyroxine replacement therapy , hormone replacement therapy ) . Antihypertensive lipid lower agent permit , must administer stable dose ( ) least 1 month Elderly Participants Cohort B Have T1DM Are T2DM participant require insulin treatment , HbA1c &gt; 10 % Have start new chronic medication ( ) change dose exist chronic medication &lt; 1 month prior dose . Participants permit continue ongoing chronic medication ( example antihypertensive agent , aspirin , nonsteroidal antiinflammatory drug , lipid lower agent , thyroxine , hormone replacement therapy , and/or oral antidiabetic participant T2DM ) . Other stable chronic condition may permit deem acceptable investigator Lilly clinical pharmacologist clinical research physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>